Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 5, 2007, Pages 1017-1020

  Rand, Kenneth H ^a   Houck, Herbert J ^a   Silverman, Jared A ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

E. faecium; Rifampicin binding site; Rpob; VRE

Indexed keywords

DAPTOMYCIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; VANCOMYCIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BIOASSAY; CONTROLLED STUDY; DRUG BINDING; DRUG BINDING SITE; ENTEROCOCCUS FAECIUM; NONHUMAN; NUCLEOTIDE SEQUENCE; WILD TYPE;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECIUM; MOLECULAR SEQUENCE DATA; RIFAMPIN; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 34447095898     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm045     Document Type: Article

References (9)

1. Steenbergen JN, Alder J, Thorne GM et al. Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005; 55: 283-8.
2. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004; 53: 530-2.
3. Campbell EA, Korzheva N, Mustaev A et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001; 104: 901-12.
4. Dabbs ER. Rifampicin inactivation by Rhodococcus and Mycobacterium species. FEMS Microbiol Lett 1987; 44: 395-9.
5. Dabbs ER, Yazawa K, Tanaka Y et al. Rifampicin inactivation by Bacillus species. J Antibiot (Tokyo) 1995; 48: 815-9.
6. Dabbs ER, Yazawa K, Mikami Y et al. Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation. Antimicrob Agents Chemother 1995; 39: 1007-9.
7. Quan S, Venter H, Dabbs ER. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob Agents Chemoter 1997; 41 2456-60.
8. Williams KJ, Piddock LJ. Accumulation of rifampicin by Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother 1998; 42: 597-603.
9. Enne VI, Delsol AA, Roe JM et al. Rifampicin resistance and its fitness cost in Enterococcus faecium. J Antimicrob Chemother 2004; 53: 203-7.